Claims for Patent: 7,462,625

Summary for Patent: 7,462,625

Title:	Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
Abstract:	GnRH receptor antagonists are disclosed that have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: ##STR00001## wherein A, Q, R.sub.1, R.sub.2, R.sub.3a, R.sub.3b, R.sub.4, R.sub.5, R.sub.6 and n are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.
Inventor(s):	Zhu; Yun-Fei (San Diego, CA), Chen; Chen (San Diego, CA), Tucci; Fabio C. (San Diego, CA), Guo; Zhiqiang (San Diego, CA), Gross; Timothy D. (San Diego, CA), Rowbottom; Martin (La Jolla, CA), Struthers; R. Scott (Encinitas, CA)
Assignee:	Neurocrine Biosciences, Inc. (San Diego, CA)
Application Number:	11/520,022
Patent Claims:	1. A compound having the following structure: ##STR02976## or a stereoisomer or pharmaceutically acceptable salt thereof, wherein: Q is a direct bond; A is O; n is 2; R.sub.1 is hydrogen or alkyl; R.sub.2 is hydrogen, alkyl or substituted alkyl; R.sub.3a and R.sub.3b are the same or different and, at each occurrence, independently hydrogen, alkyl, substituted alkyl aryl or substituted aryl; R.sub.4 is aryl, substituted aryl, heterocycle or substituted heterocycle; R.sub.5 is hydrogen or lower alkyl; and R.sub.6 is arylalkyl, substituted arylalkyl, heteroarylalkyl or substituted heteroarylalkyl. 2. A compound according to claim 1, wherein R.sub.3a is at each occurrence independently hydrogen, alkyl or aryl. 3. A compound according to claim 2, wherein R.sub.3a is at each occurrence hydrogen, methyl, isobutyl, cyclohexyl or phenyl. 4. A compound according to claim 1, wherein R.sub.3b is at each occurrence hydrogen. 5. A compound according to claim 4, wherein R.sub.4 is substituted phenyl. 6. A compound according to claim 5, wherein R.sub.4 is phenyl substituted with halogen, alkoxy, or both halogen and alkoxy. 7. A compound according to claim 1, wherein R.sub.5 is hydrogen or lower alkyl. 8. A compound according to claim 7, wherein R.sub.5 is hydrogen or methyl. 9. A compound according to claim 1, wherein R.sub.6 is arylalkyl, substituted arylalkyl, heteroarylalkyl or substituted heteroarylalkyl. 10. A compound according to claim 9, wherein R.sub.6 is benzyl or substituted benzyl. 11. A compound according to claim 1, wherein: R.sub.3a is at each occurrence independently hydrogen, methyl, isobutyl, cyclohexyl or phenyl; R.sub.3b is at each occurrence hydrogen; R.sub.4 is phenyl substituted with halogen, alkoxy, or both halogen and alkoxy; R.sub.5 is hydrogen or methyl; and R.sub.6 is benzyl or substituted benzyl. 12. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound having the following structure: ##STR02977## or a stereoisomer or pharmaceutically acceptable salt thereof, wherein: Q is a direct bond; A is O; n is 2; R.sub.1 is hydrogen or alkyl; R.sub.2 is hydrogen, alkyl or substituted alkyl; R.sub.3a and R.sub.3b are the same or different and, at each occurrence, independently hydrogen, alkyl, substituted alkyl, aryl or substituted aryl; R.sub.4 is substituted aryl or substituted heterocycle; R.sub.5 is hydrogen, lower alkyl or substituted lower alkyl; and R.sub.6 is arylalkyl, substituted arylalkyl, heteroarylalkyl or substituted heteroarylalkyl. 13. A pharmaceutical composition according to claim 12, wherein: R.sub.3a is at each occurrence hydrogen, alkyl or aryl; R.sub.3b is at each occurrence hydrogen; and R.sub.4 is substituted phenyl. 14. A pharmaceutical composition according to claim 13, wherein: R.sub.5 is hydrogen, lower alkyl or substituted lower alkyl; and R.sub.6 is arylalkyl, substituted arylalkyl, heteroarylalkyl or substituted heteroarylalkyl. 15. A pharmaceutical composition according to claim 12, wherein: R.sub.3a is at each occurrence hydrogen, methyl, isobutyl, cyclohexyl or phenyl; R.sub.3b is at each occurrence hydrogen; R.sub.4 is phenyl substituted with halogen, alkoxy, or both halogen and alkoxy; R.sub.5 is hydrogen or methyl; and R.sub.6 is benzyl or substituted benzyl. 16. A method for treating a condition selected from the group of endometriosis, polycystic ovarian disease, uterine fibroids, infertility, precocious puberty, prostatic cancer, uterine cancer, breast cancer, pituitary gonadotroph adenomas, benign prostatic hypertrophy and myoma of the uterus in a subject in need thereof comprising administering to the subject an effective amount of a compound having the following structure: ##STR02978## or a stereoisomer or pharmaceutically acceptable salt thereof, wherein: Q is a direct bond; A is O; n is 2; R.sub.1 is hydrogen or alkyl; R.sub.2 is hydrogen, alkyl or substituted alkyl; R.sub.3a and R.sub.3b are the same or different and, at each occurrence, independently hydrogen, alkyl, substituted alkyl, aryl or substituted aryl; R.sub.4 is substituted aryl or substituted heterocycle; R.sub.5 is hydrogen, lower alkyl or substituted lower alkyl; and R.sub.6 is arylalkyl, substituted arylalkyl, heteroarylalkyl or substituted heteroarylalkyl. 17. A method according to claim 16, wherein the condition is endometriosis, polycystic ovarian disease, uterine fibroids, infertility or precocious puberty. 18. A method according to claim 16, wherein the condition is endometriosis, breast cancer, uterine fibroids or benign prostatic hypertrophy. 19. A method according to claim 16, wherein the condition is endometriosis. 20. A method according to claim 16, wherein the condition is benign prostatic hypertrophy.